Acousort AB
STO:ACOU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (30.7), the stock would be worth kr10.75 (169% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.4 | kr4 |
0%
|
| 3-Year Average | 30.7 | kr10.75 |
+169%
|
| 5-Year Average | 35 | kr12.25 |
+206%
|
| Industry Average | 7.9 | kr2.76 |
-31%
|
| Country Average | 2.1 | kr0.74 |
-81%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
kr41.8m
|
/ |
Jan 2026
kr6.9m
|
= |
|
|
kr41.8m
|
/ |
Dec 2026
kr11.2m
|
= |
|
|
kr41.8m
|
/ |
Dec 2027
kr20.4m
|
= |
|
|
kr41.8m
|
/ |
Dec 2028
kr55.1m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
A
|
Acousort AB
STO:ACOU
|
84.7m SEK | 11.4 | -7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | 6.6 | 83.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 6.1 | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 5.8 | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 8.4 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 3.9 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 10.5 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 3.4 | 30.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 2.1 |
| 70th Percentile | 5.1 |
| Max | 15 188 |
Other Multiples
Acousort AB
Glance View
AcouSort AB engages in the provision of biotechnology. The company is headquartered in Lund, Skane. The company went IPO on 2017-01-09. The firm develops, produces and sells standalone laboratory products and integrated original equipment manufacturer (OEM) solutions where ultrasound is used to separate, wash and enrich cells, exosomes and other biological particles for research and diagnostics. Its product portfolio includes AcouWash and AcouTrap that are targeting separation, washing and enrichment applications within cell, bacteria and extracellular vesicle research. In addition, the Company develops proprietary bioanalytical and clinical applications based on acoustophoresis, and offers custom-developed acoustophoresis applications.
